Review: Safety of plasma volume expanders

Journal of Clinical Pharmacology

Volumn 51, Issue 3, 2011, Pages 292-300

  Farrugia, Albert ^a,b  

^a Plasma Protein Therapeutics Association   (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Albumin; colloids; pharmacovigilance; safety

Indexed keywords

ALBUMIN; DEXTRAN; GELATIN; HETASTARCH; PLASMA SUBSTITUTE; VON WILLEBRAND FACTOR; ALB PROTEIN, HUMAN; GLYCOPROTEIN; SERUM ALBUMIN;

ANALBUMINEMIA; ANAPHYLAXIS; BLOOD CLOTTING DISORDER; BOVINE SPONGIFORM ENCEPHALOPATHY; CARDIOTOXICITY; COLLOID; CRYSTALLOID; DRUG HALF LIFE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EVIDENCE BASED MEDICINE; HEART SURGERY; HEMODYNAMICS; HEMOSTASIS; HUMAN; HYPOTENSION; HYPOVOLEMIA; INCIDENCE; KIDNEY FAILURE; KIDNEY INJURY; LIVER TOXICITY; META ANALYSIS (TOPIC); MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PLASMA VOLUME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHOCK; SIDE EFFECT; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTE AGGREGATION; THROMBOELASTOGRAPHY; ANIMAL; PATHOPHYSIOLOGY;

ANIMALS; BLOOD COAGULATION DISORDERS; COLLOIDS; GLYCOPROTEINS; HUMANS; HYPOVOLEMIA; PLASMA SUBSTITUTES; RENAL INSUFFICIENCY; SERUM ALBUMIN;

EID: 79953830034     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010372107     Document Type: Review

References (90)

1. Kreimeier U. Pathophysiology of fluid imbalance. Crit Care. 2000;4:S3-S7.
2. Blundell J. Observations of transfusion of blood. Lancet. 1829;2:321-324.
3. Finlayson J. Department of Health and Human Services, Food and Drug Administration Center for Biologics Evaluation and Research. In: Proceeding from the Blood Products Advisory Committee 60th Meeting; September 17,1998; Rockville, MD. http://www.fda.gov/ohrms/dockets/AC/98/transcpt/3450t1.rtf. Accessed on May 14, 2010.
4. Hogan JJ. The intravenous use of colloidal (gelatin) solutions in shock. JAMA. 1915;64:721-726.
5. Hillman K, Bishop G, Bristow P. The crystalloid versus colloid controversy: present status. Bailliere's Clin Anaestesiol. 1997;11:1-13. (Pubitemid 27254203)
6. Gutierrez G, Reines HD, Wulf-Gutierrez ME. Clinical review: hemorrhagic shock. Crit Care. 2004;8:373-381. (Pubitemid 39468060)
7. Erstad BL, Gales BJ, Rappaport WD. The use of albumin in clinical practice. Arch Intern Med. 1991;151:901-911.
8. Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic review of randomized controlled trials. BMJ. 1998;317:235-240.
9. Wilkes MM, Navickis RJ. Patient survival after human albumin administration: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2001;135:149-164. (Pubitemid 32738309)
10. von Hoegen I, Waller C. Safety of human albumin based on spontaneously reported serious adverse events. Crit Care Med. 2001;29:994-996. (Pubitemid 32424351)
11. Vincent JL, Wilkes MM, Navickis RJ. Safety of human albumin - serious adverse events reported worldwide in 1998-2000. Br J Anaesth. 2003;91:625-630. (Pubitemid 37369521)
12. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. SAFE study investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350:2247-2256. (Pubitemid 38669207)
13. Watkins S, Madison J, Galliano M, et al. Analbuminemia: three case resulting from different point mutations in the albumin gene. Proc Natl Acad Sci USA. 1994;91:9417-9421. (Pubitemid 24297925)
14. Koot BG, Houwen R, Pot DJ, et al. Congenital analbuminaemia: biochemical and clinical implications: a case report and literature review. Eur J Pediatr. 2004;163:664-670. (Pubitemid 39517891)
15. Starling EH. On the absorption of fluids from the connective tissue spaces. J Physiol. 1896;19:312-326.
16. Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology. 2005;41:1211-1219. (Pubitemid 40770271)
17. Wunder A, Müller-Ladner U, Stelzer EH, et al. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J Immunol. 2003;170:4793-4801. (Pubitemid 36519989)
18. Reinhardt GF, Myscofski JW, Wilkens DB, et al. Incidence and mortality of hypoalbuminemic patients in hospitalized veterans. JPEN J Parenter Enteral Nutr. 1980;4:357-359.
19. Margarson MP, Soni N. Serum albumin: touchstone or totem? Anaesthesia. 1998;53:789-803.
20. Farrugia A. Albumin usage in clinical medicine: tradition or therapeutic. Transfus Med Rev. 2010;24:53-63.
21. Cohn EJ, Strong LE, Hughes WL, et al. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc. 1946;68:459-475.
22. CSL Bioplasma. Product information sheet for albumin. http://www.csl.com.au/docs/746/429/PT34500100G.pdf. Accessed on May 14, 2010.
23. Woodcock J, Griffin J, Behrman R, et al. The FDA's assessment of follow-on protein products: a historical perspective. Nat Rev Drug Discov. 2007;6:437-442. (Pubitemid 47078655)
24. Vincent JL, Navickis RJ, Wilkes MM. Morbidity in hospitalized patients receiving human albumin: a meta-analysis of randomized, controlled trials. Crit Care Med. 2004;32:2029-2038. (Pubitemid 39372536)
25. Farrugia A. The mantra of blood safety: time for a new tune? Vox Sang. 2004;86:1-7.
26. Kim IN, Eo HG, Chang CE, Lee S. Partitioning and inactivation of viruses by cold ethanol fractionation and pasteurization during manufacture of albumin from human plasma. J Microbiol Biotechnol. 2000;10:858-864.
27. Hoofnagle JH, Barker LF, Thiel J, Gerety RJ. Hepatitis B virus and hepatitis B surface antigen in human albumin products. Transfusion. 1976;16:141-147.
28. Soulier JP, Blatix C, Courouce AM, Benamon D, Amouch P, Drouet J. Prevention of virus B hepatitis (SH hepatitis). Am J Dis Child. 1972;123:429-434.
29. Foster PR. Assessment of the potential of plasma fractionation processes to remove causative agents of transmissible spongiform encephalopathy. Transfus Med. 1999;9:3-14. (Pubitemid 29134072)
30. Schosser R, Keller-Stanislawski B, Nübling CM, Löwer J. Causality assessment of suspected virus transmission by human plasma products. Transfusion. 2001;41:1020-1029. (Pubitemid 33642792)
31. Créange A, Gray F, Cesaro P, et al. Creutzfeldt-Jakob disease after liver transplantation. Ann Neurol. 1995;38:269-272.
32. Turner ML, Ironside JW. New-variant Creutzfeldt-Jakob disease: the risk of transmission by blood transfusion. Blood Rev. 1998;12:255-268. (Pubitemid 29027576)
33. Pattison CP, Klein CA, Leger RT, et al. An outbreak of type B hepatitis associated with transfusion of plasma protein fraction. Am J Epidemiol. 1976;103:399-407.
34. Alving BM, Hojima Y, Pisano JJ, et al. Hypotension associated with prekallikrein activator (Hageman-factor fragments) in plasma protein fraction. N Engl J Med. 1978;299:66-70. (Pubitemid 8405921)
35. Bleeker WK, Van Rosevelt RF, Ufkes JG, Loos JA, Van Mourik JA, Bakker JC. Hypotensive effects of plasma protein fraction. The relation between prekallikrein activator, bradykinin generation, and blood pressure in an animal model. J Lab Clin Med. 1982;100:540-547.
36. Che Y, Wilson FJ, Bertolini J, Schiff P, Maher DW. Impact of manufacturing improvements on clinical safety of albumin: Australian pharmacovigilance data for 1988-2005. Crit Care Resusc. 2006;8:334-338.
37. Yap HP, Young IF, Micucci V, Herrington RW, Turner PJ, Davies JK. Development of a process for the preparation of human serum albumin using chromatographic methods. Biotechnol Blood Proteins. 1993;227:143-149.
38. Schortgen F, Girou E, Deye N, Brochard L, CRYCO Study Group. The risk associated with hyperoncotic colloids in patients with shock. Intensive Care Med. 2008;34:2157-2168.
39. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341:403-409. (Pubitemid 29362513)
40. Jacob M, Chappell D, Conzen P, Wilkes MM, Becker BF, Rehm M. Small-volume resuscitation with hyperoncotic albumin: a systematic review of randomized clinical trials. Crit Care. 2008;12:R34.
41. Fischer MH. On hydration and "solution" in gelatin. Science. 1915;42:223-226.
42. Grobben AH, Steele PJ, Somerville RA, Taylor DM. Inactivation of the bovine-spongiform-encephalopathy (BSE) agent by the acid and alkaline processes used in the manufacture of bone gelatine. Biotechnol Appl Biochem. 2004;39:329-338. (Pubitemid 38788097)
43. Barron ME, Wilkes MM, Navickis RJ. A systematic review of the comparative safety of colloids. Arch Surg. 2004;139:552-563. (Pubitemid 38585756)
44. Ng KF, Lam CC, Chan LC. In vivo effect of haemodilution with saline on coagulation: a randomized controlled trial. Br J Anaesth. 2002;88:475-480.
45. Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol. 1994;87:106-112. (Pubitemid 24207007)
46. Egli GA, Zollinger A, Seifert B, Popovic D, Pasch T, Spahn DR. Effect of progressive haemodilution with hydroxyethyl starch, gelatin and albumin on blood coagulation. Br J Anaesth. 1997;78:684-689. (Pubitemid 27268079)
47. Niemi TT, Suojaranta-Ylinen RT, Kukkonen SI, Kuitunen AH. Gelatin and hydroxyethyl starch, but not albumin, impair hemostasis after cardiac surgery. Anesth Analg. 2006;102:998-1006.
48. Van der Linden P, Ickx BE. The effects of colloid solutions on hemostasis. Can J Anaesth. 2006;53:S30-S39. (Pubitemid 44150883)
49. Karoutsos S, Nathan N, Lahrimi A, Grouille D, Feiss P, Cox DJ. Thrombelastogram reveals hypercoagulability after administration of gelatin solution. Br J Anaesth. 1999;82:175-177. (Pubitemid 29057611)
50. Niemi TT, Kuitunen AH. Artificial colloids impair haemostasis. An in vitro study using thromboelastometry coagulation analysis. Acta Anaesthesiol Scand. 2005;49:373-378.
51. de Jonge E, Levi M, Berends F, van der Ende AE, ten Cate JW, Stoutenbeek CP. Impaired haemostasis by intravenous administration of a gelatin-based plasma expander in human subjects. Thromb Haemost. 1998;79:286-290.
52. Batlle J, del Río F, López Fernández MF, Martín R, López Borrasca A. Effect of dextran on factor VIII/von Willebrand factor structure and function. Thromb Haemost. 1985;54:697-699. (Pubitemid 16195321)
53. Stump DC, Strauss RG, Henriksen RA, Petersen RE, Saunders R. Effects of hydroxyethyl starch on blood coagulation, particularly factor VIII. Transfusion. 1985;25:349-354. (Pubitemid 15242039)
54. Farrugia A, Griffin B, Pepper D, Prowse C. Studies on the procurement of coagulation factor VIII: selective precipitation of factor VIII with hydrophilic polymers. Thromb Haemost. 1984;51:338-342. (Pubitemid 14097887)
55. Samama CM. Dextan and hemostasis. In: Baron JF, ed. Plasma Volume Expansion. Paris: Arnette; 1992:97-104.
56. Treib J, Baron JF. Hydroxyethyl starch: effects on hemostasis. Ann Fr Anesth Réanim. 1998;17:72-81.
57. Knutson JE, Deering JA, Hall FW, et al. Does intraoperative hetastarch administration increase blood loss and transfusion requirements after cardiac surgery? Anesth Analg. 2000;90:801-807.
58. Jamnicki M, Zollinger A, Seifert B, Popovic D, Pasch T, Spahn DR. Compromised blood coagulation: an in vitro comparison of hydroxyethyl starch 130/0.4 and hydroxyethyl starch 200/0.5 using thrombelastography. Anesth Analg. 1998;87:989-993. (Pubitemid 28501146)
59. Thyes C, Madjdpour C, Frascarolo P, et al. Effect of high- and low-molecular weight low-substituted hydroxyethyl starch on blood coagulation during acute normovolemic hemodilution in pigs. Anesthesiology. 2006;105:1228-1237. (Pubitemid 44808587)
60. De Lorenzo C, Calatzis A, Welsch U, Heindl B. Fibrinogen concentrate reverses dilutional coagulopathy induced in vitro by saline but not by hydroxyethyl starch 6%. Anesth Analg. 2006;102:1194-1200.
61. Jungheinrich C, Sauermann W, Bepperling F, Vogt NH. Volume efficacy and reduced influence on measures of coagulation using hydroxyethyl starch 130/0.4 (6%) with an optimised in vivo molecular weight in orthopaedic surgery: a randomised, double-blind study. Drugs R D. 2004;5:1-9.
62. Gallandat Huet RC, Siemons AW, Baus D, et al. A novel hydroxyethyl starch (Voluven) for effective perioperative plasma volume substitution in cardiac surgery. Can J Anaesth. 2000;47:1207-1215. (Pubitemid 32098997)
63. Langeron O, Doelberg M, Ang ET, Bonnet F, Capdevila X, Coriat P. Voluven, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5. Anesth Analg. 2001;92:855-862. (Pubitemid 32239122)
64. Kozek-Langenecker SA, Jungheinrich C, Sauermann W, Van der Linden P. The effects of hydroxyethyl starch 130/0.4 (6%) on blood loss and use of blood products in major surgery: a pooled analysis of randomized clinical trials. Anesth Analg. 2008;107:382-390.
65. Harzog C, Brunkhorst F, Reinhart K, et al. Hydroxyethyl starch 130/0.4 and surgical blood loss. Anesth Analg. 2009;108:672-673.
66. Sander O, Reinhart K, Meier-Hellmann A. Equivalence of hydroxyethyl starch HES 130/0.4 and HES 200/0.5 for perioperative volume replacement in major gynaecological surgery. Acta Anaesthesiol Scand. 2003;47:1151-1158. (Pubitemid 37108508)
67. Boldt J, Suttner S, Brosch C, Lehmann A, Mengistu A. Influence on coagulation of a potato-derived hydroxethylstarch (HES 130/0.42) and a maize-derived hydroxethylstarch (HES 130/0.4) in patients undergoing cardiac surgery. Br J Anaesth. 2009;102:191-197.
68. Neff TA, Doelberg M, Jungheinrich C, Sauerland A, Spahn DR, Stocker R. Repetitive large-dose infusion of the novel hydroxyethyl starch 130/0.4 in patients with severe head injury. Anesth Analg. 2003;96:1453-1459. (Pubitemid 36512891)
69. Kasper SM, Meinert P, Kampe S, et al. Large-dose hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with hydroxyethyl starch 200/0.5 at recommended doses. Anesthesiology. 2003;99:42-47. (Pubitemid 36799031)
70. Schramko AA, Suojaranta-Ylinen RT, Kuitunen AH, Kukkonen SI, Niemi TT. Rapidly degradable hydroxyethyl starch solutions impair blood coagulation after cardiac surgery: a prospective randomized trial. Anesth Analg. 2009;108:30-36.
71. Review of Voluven, 2007. Food and Drug Administration Web site. http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/ NewDrugApplicationsNDAs/ucm083145.htm. Accessed on May 14, 2010.
72. Gottstein U. Treatment of inadequate cerebral circulation. A critical review. Internist (Berl). 1974;15:575-587.
73. Matheson NA, Diomi P. Renal failure after the administration of dextran 40. Surg Gynecol Obstet. 1970;131:661-668.
74. Moran M, Kapsner C. Acute renal failure associated with elevated plasma oncotic pressure. N Engl J Med. 1987;317:150-153. (Pubitemid 17096463)
75. Waldhausen P, Kiesewetter H, Leipnitz G, et al. Hydroxyethyl starch induced transient renal failure in preexisting glomerular damage. Acta Med Austriaca. 1991;18:52-55.
76. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358:125-139.
77. Boldt J, Brenner T, Lehmann A, Lang J, Kumle B, Werling C. Influence of two different volume replacement regimens on renal function in elderly patients undergoing cardiac surgery: comparison of a new starch preparation with gelatin. Intensive Care Med. 2003;29:763-769. (Pubitemid 36609569)
78. Jungheinrich C, Scharpf R, Wargenau M, Bepperling F, Baron JF. The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500 mL) in mild-to-severe renal impairment. Anesth Analg. 2002;95:544-551. (Pubitemid 35006837)
79. Wiedermann CJ. Systematic review of randomized clinical trials on the use of hydroxyethyl starch for fluid management in sepsis. BMC Emerg Med. 2008;8:1.
80. Hussain SF, Drew PJ. Acute renal failure after infusion of gelatins. BMJ. 1989;299:1137-1138. (Pubitemid 19266424)
81. Legendre C, Thervet E, Page B, Percheron A, Noël LH, Kreis H. Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation. Lancet. 1993;342:248-249. (Pubitemid 23214667)
82. Cittanova ML, Leblanc I, Legendre C, Mouquet C, Riou B, Coriat P. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet. 1996;348:1620-1622. (Pubitemid 27007061)
83. Blasco V, Leone M, Antonini F, Geissler A, Albanese J, Martin C. Comparison of the novel hydroxyethylstarch 130/0.4 and hydroxyethylstarch 200/0.6 in braindead donor resuscitation on renal function after transplantation. Br J Anaesth. 2008;100:504-508. (Pubitemid 351773604)
84. Zarychanski R, Turgeon AF, Fergusson DA, et al. Renal outcomes and mortality following hydroxyethyl starch resuscitation of critically ill patients: systematic review and meta-analysis of randomized trials. Open Medicine. 2009;3:e196-209.
85. Dart AB, Mutter TC, Ruth CA, Taback SP. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev. 2010. [Epub ahead of print: DOI 10.1002/14651858.CD007594.pub2.]
86. Matejtschuk P, Dash CH, Gascoigne EW. Production of human albumin solution: a continually developing colloid. Br J Anaesth. 2000;85:887-895.
87. Nohé B, Dieterich HJ, Eichner M, Unertl K. Certain batches of albumin solutions influence the expression of endothelial cell adhesion molecules. Intensive Care Med. 1999;25:1381-1385. (Pubitemid 30021164)
88. Klammt S, Brinkmann B, Mitzner S, et al. Albumin binding capacity (ABiC) is reduced in commercially available human serum albumin preparations with stabilizers. Z Gastroenterol. 2001;39:24-27.
89. Heringlake M, Brückner S, Schmucker P. Different batches of human albumin solutions from one manufacturer may induce heterogenous cardiovascular effects. Intensive Care Med. 2000;26:1011-1012. (Pubitemid 30616062)
90. Boldt J, Schölhorn T, Mayer J, Piper S, Suttner S. The value of an albumin-based intravascular volume replacement strategy in elderly patients undergoing major abdominal surgery. Anesth Analg. 2006;103:191-199. (Pubitemid 44036058)